Foghorn Therapeutics
Cigall Kadoch, PhD, is an assistant professor of pediatric oncology at the Dana-Farber Cancer Institute, assistant professor of biological chemistry and molecular biology at Harvard Medical School, and Institute member and co-director of the epigenomics program at the Broad Institute of MIT and Harvard.
Cigall established her independent laboratory in 2014 at the age of 27, immediately following completion of her PhD studies in cancer biology at Stanford University. She is one of the youngest scientists ever appointed to the Harvard Medical School faculty. She has quickly become a leading expert in chromatin and gene regulation and is internationally recognized for her groundbreaking studies in these areas.
In addition to receiving numerous prestigious awards and research grants to support her academic laboratory at Harvard—including the NIH Director’s New Innovator Award, the Pew Scholar Award, and the American Cancer Society Research Scholar Award—Cigall was named to the Forbes 2014 30 Under 30 list, MIT Technology Review’s 35 Innovators Under 35, Popular Science Brilliant 10 of 2016, and most recently Business Insider’s Top 30 Young Leaders in Biopharma.
Cigall holds a BA in molecular and cellular biology from the University of California, Berkeley, and a PhD in cancer biology from the Stanford University School of Medicine.
This person is not in the org chart
This person is not in any offices
Foghorn Therapeutics
1 followers
Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Their proprietary Gene Traffic Control platform gives them an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing them to identify, validate, and potential drug targets within the system.